All In Biotech

Drug Trial Radar · NCT03955380

MAD Phase I Study to Investigate Contraloid Acetate

Single-center, Randomized, Prospective, Double-blind, Placebo Controlled Phase Ib Study With an Adaptive Multiple Ascending Dose (MAD) Design to Investigate the Safety, Tolerability, Pharmacokinetics of Contraloid Acetate (Healthy Subjects)

Last checked: Nov 19, 2026Latest source record: May 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Dec 12, 2018

Primary completion

Apr 3, 2019

Study completion Apr 3, 2019

Sponsor

Lead sponsor
Prof. Dr. Dieter WillboldAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Helmholtz-Gemeinschaft Deutscher Forschungszentren, Germany; Medical University of Vienna; NeuroScios, Austria; Nuvisan, Germany; Fundación Teófilo Hernando, Spain; Alzheimer's Association
First posted
May 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, alias PRI-002) is an orally available all-D-peptide, which was developed to directly destroy toxic and replicating A-beta oligomer prions, by disassembling them into A-beta monomers. The study drug is specifically designed for the curative or at least disease-modifying treatment of cognition, memory and behavior deficits in Alzheimer´s disease patients. The study drug is BBB penetrable \[1\] and has demonstrated target engagement in vitro and in vivo \[2, 3\]. Treatments in three different transgenic mouse models in three different laboratories yielded improved cognition and deceleration of neurodegeneration, even under truly non-preventive treatment conditions and even when applied orally \[2-5\]. The hereby obtained PRI-002 plasma levels have also been achieved in humans after single oral dosing.

Conditions

  • Alzheimer Dementia
  • Alzheimer Disease

Interventions

  • ContraloidDrug

    Oral administration of capsules, drug substance or placebo without any exipients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of safety and tolerability of Contraloid by monitoring vital signs, ECG and lab valuesTime frame: 21 days for cohort 1 and 35 days for cohort 2
  2. Assessment of pharmacokinetics of Contraloid: Area under curve (AUC) in plasmaTime frame: 168 hours
  3. Assessment of pharmacokinetics of Contraloid: Cmax in plasmaTime frame: 21/35 days
  4. Assessment of pharmacokinetics of Contraloid: Tmax in plasmaTime frame: 21/35 days
  5. Assessment of pharmacokinetics of Contraloid: Terminal elimination half-life (t1/2) in plasmaTime frame: 21/35 days
  6. Assessment of pharmacokinetics of Contraloid: distributive half-life (t1/2alpha) in plasmaTime frame: 21/35 days
  7. Assessment of pharmacokinetics of Contraloid: terminal elimination half-life (t1/2beta) in plasmaTime frame: 21/35 days
  8. Assessment of pharmacokinetics of Contraloid: Elimination Constant (Kel alpha) in plasmaTime frame: 21/35 days
  9. Assessment of pharmacokinetics of Contraloid: Elimination Constant (Kel beta) in plasmaTime frame: 21/35 days
  10. AUC0-24 of Contraloid does not exceed of 2.3 µg·h/mLTime frame: 21/35 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Forschungszentrum Jülich

    Jülich, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.